| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 155, Issue 3 1544-1555, Copyright © 1995 by American Association of Immunologists
ARTICLES |
ML Alegre, JY Tso, HA Sattar, J Smith, F Desalle, M Cole and JA Bluestone
Ben May Institute, Department of Pathology, University of Chicago, IL 60637, USA.
145-2C11, a hamster mAb directed against the mouse CD3 complex, is a potent immunosuppressive agent. Upon initial treatment, 145-2C11 triggers a systemic release of multiple cytokines that is responsible for the acute toxicity of the mAb. This cellular activation is a consequence of the cross-linking between T lymphocytes and Fc gamma R- bearing cells, mediated by the high affinity of the hamster mAb for murine Fc gamma Rs. Repeated mAb injections result in the onset of a neutralizing humoral response. Therefore, there has been an increased interest in developing nonmitogenic forms of anti-CD3 mAbs, although it is not clear whether these Abs will retain immunosuppressive properties. To determine whether the initial cytokine production is necessary for the immunosuppressive properties and the immunogenicity of anti-CD3 mAbs in vivo, we have generated chimeric (hamster 145-2C11 F(ab')2 region/mouse Fc gamma portion) mAbs using murine isotypes with different affinities for Fc gamma Rs. The 145-2C11 and a chimeric IgG2a isotype, both of which bind murine Fc gamma Rs avidly, had similar activating, immunogenic, and immunosuppressive properties in mice. The administration of a chimeric IgG3 isotype with a very low affinity for murine Fc gamma Rs did not result in cytokine production, a humoral response against the mAb, or TCR desensitization. Nevertheless, prolongation of skin graft survival was similar in the IgG3, IgG2a, and 145-2C11-treated mice, indicating that Fc gamma R nonbinding anti-CD3 mAbs retain potent immunosuppressive properties in vivo while not being immunogenic. This enhanced therapeutic to toxic profile may be beneficial in clinical transplantation.
This article has been cited by other articles:
|
|
 |
|
  B. Z. Alizadeh, G. Valdigem, M. J.H. Coenen, A. Zhernakova, B. Franke, A. Monsuur, P. L.C.M. van Riel, P. Barrera, T. R.D.J. Radstake, B. O. Roep, et al. Association analysis of functional variants of the FcgRIIa and FcgRIIIa genes with type 1 diabetes, celiac disease and rheumatoid arthritis Hum. Mol. Genet., November 1, 2007; 16(21): 2552 - 2559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Kamimura and M. J. Bevan Naive CD8+ T cells differentiate into protective memory-like cells after IL-2 anti IL-2 complex treatment in vivo J. Exp. Med., August 6, 2007; 204(8): 1803 - 1812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. T. Fife, I. Guleria, M. Gubbels Bupp, T. N. Eagar, Q. Tang, H. Bour-Jordan, H. Yagita, M. Azuma, M. H. Sayegh, and J. A. Bluestone Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway J. Exp. Med., November 27, 2006; 203(12): 2737 - 2747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Ochando, A. C. Yopp, Y. Yang, A. Garin, Y. Li, P. Boros, J. Llodra, Y. Ding, S. A. Lira, N. R. Krieger, et al. Lymph Node Occupancy Is Required for the Peripheral Development of Alloantigen-Specific Foxp3+ Regulatory T Cells J. Immunol., June 1, 2005; 174(11): 6993 - 7005. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Kohm, J. S. Williams, A. L. Bickford, J. S. McMahon, L. Chatenoud, J.-F. Bach, J. A. Bluestone, and S. D. Miller Treatment with Nonmitogenic Anti-CD3 Monoclonal Antibody Induces CD4+ T Cell Unresponsiveness and Functional Reversal of Established Experimental Autoimmune Encephalomyelitis J. Immunol., April 15, 2005; 174(8): 4525 - 4534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Bluestone and Q. Tang Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells PNAS, October 5, 2004; 101(suppl_2): 14622 - 14626. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Yang, S. Hussain, Q.-S. Mi, P. Santamaria, and T. L. Delovitch Perturbed Homeostasis of Peripheral T Cells Elicits Decreased Susceptibility to Anti-CD3-Induced Apoptosis in Prediabetic Nonobese Diabetic Mice J. Immunol., October 1, 2004; 173(7): 4407 - 4416. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Tang, S. K. Subudhi, K. J. Henriksen, C. G. Long, F. Vives, and J. A. Bluestone The Src Family Kinase Fyn Mediates Signals Induced by TCR Antagonists J. Immunol., May 1, 2002; 168(9): 4480 - 4487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Carpenter, S. Pavlovic, J. Y. Tso, O. W. Press, T. Gooley, X.-Z. Yu, and C. Anasetti Non-Fc Receptor-Binding Humanized Anti-CD3 Antibodies Induce Apoptosis of Activated Human T Cells J. Immunol., December 1, 2000; 165(11): 6205 - 6213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kouki, Y. Sawai, C. A. Gardine, M.-E. Fisfalen, M.-L. Alegre, and L. J. DeGroot CTLA-4 Gene Polymorphism at Position 49 in Exon 1 Reduces the Inhibitory Function of CTLA-4 and Contributes to the Pathogenesis of Graves' Disease J. Immunol., December 1, 2000; 165(11): 6606 - 6611. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Korthauer, W. Nagel, E. M. Davis, M. M. Le Beau, R. S. Menon, E. O. Mitchell, C. A. Kozak, W. Kolanus, and J. A. Bluestone Anergic T Lymphocytes Selectively Express an Integrin Regulatory Protein of the Cytohesin Family J. Immunol., January 1, 2000; 164(1): 308 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Muraille, F. Andris, B. Pajak, K. M. Wissing, T. De Smedt, F. Desalle, M. Goldman, M.-L. Alegre, J. Urbain, M. Moser, et al. Downregulation of Antigen-Presenting Cell Functions After Administration of Mitogenic Anti-CD3 Monoclonal Antibodies in Mice Blood, December 15, 1999; 94(12): 4347 - 4357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Chau, J. A. Bluestone, and J. Madrenas Dissociation of Intracellular Signaling Pathways in Response to Partial Agonist Ligands of the T Cell Receptor J. Exp. Med., May 18, 1998; 187(10): 1699 - 1709. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Smith, Q. Tang, and J. A. Bluestone Partial TCR Signals Delivered by FcR-Nonbinding Anti-CD3 Monoclonal Antibodies Differentially Regulate Individual Th Subsets J. Immunol., May 15, 1998; 160(10): 4841 - 4849. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Smith, J. Y. Tso, M. R. Clark, M. S. Cole, and J. A. Bluestone Nonmitogenic Anti-CD3 Monoclonal Antibodies Deliver a Partial T Cell Receptor Signal and Induce Clonal Anergy J. Exp. Med., April 21, 1997; 185(8): 1413 - 1422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Wang, S. Zinkel, K. Polonsky, and E. Fuchs Transgenic studies with a keratin promoter-driven growth hormone transgene: Prospects for gene therapy PNAS, January 7, 1997; 94(1): 219 - 226. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
